SI1242410T1 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SI1242410T1
SI1242410T1 SI200030501T SI200030501T SI1242410T1 SI 1242410 T1 SI1242410 T1 SI 1242410T1 SI 200030501 T SI200030501 T SI 200030501T SI 200030501 T SI200030501 T SI 200030501T SI 1242410 T1 SI1242410 T1 SI 1242410T1
Authority
SI
Slovenia
Prior art keywords
novel compounds
compounds
directed
general formula
present application
Prior art date
Application number
SI200030501T
Other languages
English (en)
Slovenian (sl)
Inventor
William c/o AstraZeneca R & D Montreal BROWN
Christopher AstraZeneca R & D Montreal WALPOLE
Niklas Plobeck
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1242410T1 publication Critical patent/SI1242410T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Furan Compounds (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Liquid Crystal (AREA)
SI200030501T 1999-12-20 2000-12-15 Novel compounds SI1242410T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9904674A SE9904674D0 (sv) 1999-12-20 1999-12-20 Novel compounds
PCT/SE2000/002562 WO2001046174A1 (en) 1999-12-20 2000-12-15 Novel compounds
EP00987916A EP1242410B1 (en) 1999-12-20 2000-12-15 Novel compounds

Publications (1)

Publication Number Publication Date
SI1242410T1 true SI1242410T1 (en) 2004-12-31

Family

ID=20418210

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030501T SI1242410T1 (en) 1999-12-20 2000-12-15 Novel compounds

Country Status (31)

Country Link
US (2) US6680318B2 (enExample)
EP (1) EP1242410B1 (enExample)
JP (1) JP2003522741A (enExample)
KR (2) KR20070090050A (enExample)
CN (1) CN1608064A (enExample)
AT (1) ATE275143T1 (enExample)
AU (1) AU780799B2 (enExample)
BG (1) BG65457B1 (enExample)
BR (1) BR0016591A (enExample)
CA (1) CA2395300A1 (enExample)
CZ (1) CZ20022124A3 (enExample)
DE (1) DE60013486T2 (enExample)
DK (1) DK1242410T3 (enExample)
EE (1) EE200200337A (enExample)
ES (1) ES2225289T3 (enExample)
HK (1) HK1048308B (enExample)
HU (1) HUP0300020A3 (enExample)
IL (2) IL150125A0 (enExample)
IS (1) IS2143B (enExample)
MX (1) MXPA02006063A (enExample)
NO (1) NO322432B1 (enExample)
NZ (1) NZ519986A (enExample)
PL (1) PL356780A1 (enExample)
PT (1) PT1242410E (enExample)
RU (1) RU2258703C2 (enExample)
SE (1) SE9904674D0 (enExample)
SI (1) SI1242410T1 (enExample)
SK (1) SK8832002A3 (enExample)
UA (1) UA71650C2 (enExample)
WO (1) WO2001046174A1 (enExample)
ZA (1) ZA200204255B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
NZ539828A (en) * 2001-05-18 2007-01-26 Astrazeneca Ab 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
JP4892654B2 (ja) * 2001-10-29 2012-03-07 マウント クック ファーマ，インコーポレーテッド デルタレセプターアゴニスト化合物によるうつ病の治療方法
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
CN1890208A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 类鸦片受体拮抗剂
SE0400027D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
KR101234421B1 (ko) 2004-08-02 2013-02-18 아스트라제네카 아베 디아릴메틸 피페라진 유도체, 이의 제조 방법 및 용도
CN101128447A (zh) * 2005-02-28 2008-02-20 阿斯利康(瑞典)有限公司 二芳基甲基哌嗪衍生物，其制备及其用途
GB0606876D0 (en) * 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
EA201001644A1 (ru) * 2008-05-20 2011-06-30 Астразенека Аб Способ лечения тревожного большого депрессивного расстройства

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585209A5 (enExample) 1973-06-29 1977-02-28 Cermol Sa
DE2900810A1 (de) 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
IT1140978B (it) 1980-05-23 1986-10-10 Selvi & C Spa 1-(4-clorobenzidril)-4-(2,3-diidros sipropil)-piperazina, metodi per la sua preparazione e relative composizione farmaceutiche
GB8320701D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IT1196150B (it) 1984-06-19 1988-11-10 Poli Ind Chimica Spa Derivati di 1-(bis-(4-fluorofenil)metil)-4-(3-fenil-2-propenil)-esaidro-1h-1,4-diazepina ad attivita' calcio antagonista,sua preparazione e composizioni che lo contengono
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4829065A (en) 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
RU2093156C1 (ru) 1989-11-22 1997-10-20 Жансен Фармасетика Н.В. L-(-)-2-(аминокарбонил)-n-(4-амино-2,6-дихлорфенил-4[5,5-бис(4-фторфенил)пентил]-1-пиперазинацетамид, его фармацевтически приемлемая кислотно-аддитивная соль или гидрат, способ его получения и средство для хранения сердца донора
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5807858A (en) 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
FR2696744B1 (fr) 1992-10-12 1994-12-30 Logeais Labor Jacques Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
WO1995004051A1 (en) 1993-07-30 1995-02-09 The Wellcome Foundation Limited Piperazine compounds used in therapy
JP3352184B2 (ja) 1993-11-12 2002-12-03 株式会社アズウェル ピペラジン不飽和脂肪酸誘導体
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US5693843A (en) * 1995-12-22 1997-12-02 E. I. Du Pont De Nemours And Company Process for hydrocyanation of diolefins and isomerization of nonconjugated 2 alkyl-3-monoalkenenitriles
SE9604786D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
CA2316341A1 (en) 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds

Also Published As

Publication number Publication date
NO20022920L (no) 2002-07-22
NO322432B1 (no) 2006-10-02
BG106805A (en) 2003-03-31
MXPA02006063A (es) 2003-02-06
HK1048308B (en) 2005-04-08
IL150125A (en) 2006-08-20
ATE275143T1 (de) 2004-09-15
CA2395300A1 (en) 2001-06-28
EP1242410B1 (en) 2004-09-01
DE60013486D1 (de) 2004-10-07
JP2003522741A (ja) 2003-07-29
DK1242410T3 (da) 2004-11-29
AU2418401A (en) 2001-07-03
IS6426A (is) 2002-06-18
US20040138225A1 (en) 2004-07-15
CN1608064A (zh) 2005-04-20
KR20020062350A (ko) 2002-07-25
SK8832002A3 (en) 2003-03-04
PL356780A1 (en) 2004-07-12
HUP0300020A3 (en) 2005-02-28
RU2258703C2 (ru) 2005-08-20
CZ20022124A3 (cs) 2002-11-13
NZ519986A (en) 2004-06-25
KR20070090050A (ko) 2007-09-04
NO20022920D0 (no) 2002-06-18
IS2143B (is) 2006-09-15
WO2001046174A1 (en) 2001-06-28
EP1242410A1 (en) 2002-09-25
US6680318B2 (en) 2004-01-20
BR0016591A (pt) 2002-09-10
KR100769814B1 (ko) 2007-10-23
EE200200337A (et) 2003-10-15
ES2225289T3 (es) 2005-03-16
SE9904674D0 (sv) 1999-12-20
UA71650C2 (uk) 2004-12-15
IL150125A0 (en) 2002-12-01
RU2002114343A (ru) 2004-01-10
BG65457B1 (bg) 2008-08-29
AU780799B2 (en) 2005-04-21
HK1048308A1 (en) 2003-03-28
DE60013486T2 (de) 2005-11-17
US20030105110A1 (en) 2003-06-05
PT1242410E (pt) 2004-12-31
ZA200204255B (en) 2003-08-28
HUP0300020A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
NZ335981A (en) Ketobenzamides as calpain inhibitors
GB0005251D0 (en) Therapeutic compounds
MY132705A (en) Novel compounds with analgesic effect
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
ZA988158B (en) Sulfinic acid derivatives and their preparation and use
MY121294A (en) Novel hexanoic acid derivatives.
MY111201A (en) New imidazopyridines
GR3030751T3 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
DE69925133D1 (de) Pyrrolobenzodiazepine
IL150125A0 (en) Novel compounds
AP2001002318A0 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
ZA9710796B (en) Oxyiminopregnanecarbolactones.
IT1285770B1 (it) Composti corticoidei
NZ513096A (en) Compositions for treating inflammatory response
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
IL135825A0 (en) Use of mirtazapine for treating sleep apneas
GB0018951D0 (en) Novel compounds
GB0027705D0 (en) Novel compounds
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
DK1294732T3 (da) Ruthenium (II)-forbindelser til anvendelse i cancerterapi
GB9626472D0 (en) New use of comt inhibitors
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.